By Mia Lamar

Among the companies with shares expected to actively trade in Monday's session are Bristol-Myers Squibb Co. (BMY), Pfizer Inc. (PFE) and Momenta Pharmaceuticals Inc. (MNTA).

Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) said the U.S. Food and Drug Administration has requested more information on their anti-clotting drug Eliquis. The request pushes back the potential for U.S. sales of the drug, which is already approved in Europe. Shares of the smaller Bristol-Myers dropped 4.6% to $33.75 in premarket trading while Pfizer shares were last trading down 2.3% to $22.21.

Teva Pharmaceutical Industries Ltd. (TEVA) said a U.S. district court validated its patents for the multiple-sclerosis drug Copaxone and found purported generic versions by Mylan Inc. (MYL) and Momenta Pharmaceuticals Inc. (MNTA) infringe those patents. The news lifted Teva shares 7% to $40.70 premarket, while sending Momenta shares plunging 21% to $13.50 premarket. Shares of the larger Mylan were trading slightly lower at $21.10.

Ventrus Biosciences Inc.'s (VTUS) hemorrhoidal disease treatment iferanserin failed to meet primary endpoints in a Phase 3 trial. Shares of the development-stage pharmaceutical plunged plunged 57% to $5.21 premarket as it said it has no immediate plans to continue the drug's development.